ELTX vs MRNA
ELTX: Elicio develops lymph node-targeted "off-the-shelf" cancer immunotherapies using proprietary AMP technology to generate robust T cell responses against common KRAS mutations in pancreatic, colorectal, and other solid tumors. MRNA: Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and declining sales.
Side-by-side fundamentals
| Metric | ELTX | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.12 | $58.07 | |
| Market cap as of 2026-07-23 | $73M | $22.9B | |
| Net margin as of 2026-07-23 | -81.5% | -143.6% | ELTX higher |
| Gross margin as of 2026-07-23 | +98.5% | +35.0% | ELTX higher |
| Operating margin as of 2026-07-23 | -83.0% | -153.3% | ELTX higher |
| ROE as of 2026-07-23 | -977.7% | -36.7% | MRNA higher |
| ROA as of 2026-07-23 | -151.1% | -26.6% | MRNA higher |
| Debt / equity as of 2026-07-23 | 5.75 | 0.09 | MRNA lower |
| Revenue growth (YoY) as of 2026-07-23 | -91.9% | -30.0% | MRNA higher |
| Revenue CAGR (3y) SEC XBRL | -10.6% | -53.4% | ELTX higher |
| Beta as of 2026-07-23 | 1.30 | 0.88 | |
| 1-year return as of 2026-07-22 close | -66.7% | +77.4% | MRNA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.